Abstract
Purpose. The attainment of effective intracellular delivery remains an important issue for pharmacologic applications of antisense oligonucleotides. Here, we describe the synthesis, binding properties, and biologic properties of peptide-oligonucleotide conjugates comprised of the Tat and Ant cell-penetrating peptides with 2′-O-methyl phosphorothioate oligonucleotides.
Methods. The biologic assay used in this study measures the ability of the antisense molecule to correct splicing of an aberrant intron inserted into the Luciferase gene; thus, this assay clearly demonstrates the delivery of functional antisense molecules to the splicing machinery within the nucleus. The binding affinities of the conjugates to their target sequences were measured by surface plasmon resonance (BIAcor) techniques.
Results. The peptide-oligonucleotide conjugates progressively entered cells over a period of hours and were detected in cytoplasmic vesicles and in the nucleus. Peptide-oligonucleotide conjugates targeted to the aberrant splice site, but not mismatched controls, caused an increase in Luciferase activity in a dose-responsive manner. The kinetics of Luciferase appearance were consistent with the course of the uptake process for the conjugates. The effects of peptide conjugation on the hybridization characteristics of the oligonucleotides were also examined using surface plasmon resonance. The peptide-oligonucleotide conjugates displayed binding affinities and selectivities similar to those of unconjugated oligonucleotides.
Conclusions. Conjugation with cell-penetrating peptides enhances oligonucleotide delivery to the nucleus without interfering with the base-pairing function of antisense oligonucleotides.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
C. F. Bennett. Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55:9–19 (1998).
C. A. Stein and Y.-C. Cheng. Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 261:1004–1012 (1993).
P. Wittung-Stafshede. Genetic medicine-when will it come to the drugstore. Science 281:657–658 (1998).
P. T. Ho and D. R. Parkinson. Antisense oligonucleotides as therapeutics for malignant diseases. Semin. Oncol. 24:187–202 (1997).
J. S. Waters, A. Webb, D. Cunningham, P. A. Clarke, F. Raynaud, F. di Stefano, and F. E. Cotter. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18: 1812–1823 (2000).
S. T. Crooke. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489:31–44 (1999).
A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak. Nucleic acid therapeutics: state of the art future prospects. Blood 92:712–736 (1998).
R. L. Juliano, S. Alahari, H. Yoo, R. Kole, and M. Cho. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16:494–502 (1999).
J. G. Lewis. K.-Y. Lin, A. Kothavale, W. M. Flanagan, M. D. Matteucci, R. B. DePrincr, R. A. J. Mook, R. W. Hendren, and R. W. Wagner. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA 93:3176–3181 (1996).
P. L. Felgner, Y. J. Tsai, L. Sukhu, C. J. Wheeler, M. Manthorpe, J. Marshall, and S. H. Cheng. Improved cationic lipid formulations for in vivo gene therapy. Ann. N.Y. Acad. Sci. 772:126–139 (1995).
R. DeLong, K. Stephenson, T. Loftus, S. K. Alahari, M. H. Fisher, and R. L. Juliano. Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J. Pharm. Sci. 86:762–764 (1997).
H. Yoo, P. Sazani, and R. L. Juliano. PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm. Res. 16: 1799–1804 (1999).
M. Lindgren, M. Hallbrink, A. Prochiantz, and U. Langel. Cell-penetrating peptides. Trends Pharm. Sci. 21:99–103 (2000).
R. L. Juliano and H. Yoo. Aspects of the transport and delivery of antisense oligonucleotides. Curr. Opin. Mol. Ther. 2:297–303 (2000).
S. Falwell, J. Seery, Y. Daikh, C. Moore, L. L. Chen, B. Pepinsky, and J. Barsooum. Tat mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91:664–668 (1994).
D. Derossi, S. Calvet, A. Trembleau, A. Brunissen, G. Chassaing, and A. Prochiantz. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271:18188–18193 (1996).
E. Vives, P. Brodin, and B. Lebleu. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272: 16010–16017 (1997).
G. Aldrian-Herrada, M. G. Desarmenien, H. Orcel, L. Boissin-Agasse, J. Mery, J. Brugidou, and A. Rabie. A peptide nucleic acid (PNA) is more rapidly internalized in culturerd neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res. 26:4910–4916 (1998).
M. Pooga, U. Soomets, M. Hallbrink, A. Valkna, K. Saar, K. Rezaei, U. Kahl. J. X. Hau, X. J. Xu, Z. Wiesenfeld-Hallin, T. Hokfelt, T. Bartfai, and U. Langel. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:857–861 (1998).
A. Astriab-Fisher, D. S. Sergueev, M. Fisher, B. R. Shaw, and R. L. Juliano. Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem. Pharmacol. 60: 83–90 (2000).
H. Nagahara, A. M. Vocero-Akbani, E. L. Snyder, A. Ho, D. G. Latham, N. A. Lissy, M. Becker-Hapak, S. A. Ezhevshy, and S. F. Dowdy. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4:1449–1452 (1998).
S. R. Schwarze, A. Ho, A. Vocero-Akbani, and S. F. Dowdy. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–1572 (1999).
R. Kole. Modification of pre-mRNA splicing by antisense oligonucleotides. In C. A. Stein and A. M. Krieg (eds.), Applied Antisense Oligonucleotide Technology Willey-Liss, Inc., New York, 1998 pp. 451–469.
H. Sierakowska, M. J. Sambade, S. Agrawal, and R. Kole. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93:12840–12844 (1996).
G. Lacerra, H. Sierakowska, C. Carestia, S. Fucharoen, J. Summerton, D. Weller, and R. Kole. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA 97:9591–9596 (2000).
S. H. Kang, M. J. Cho, and R. Kole. Up-regulation of the luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37:6235–6239 (1998).
E. Vives and B. Lebleu. Selective coupling of a highly basic peptide to an oligonucleotide. Tetrahedron Lett. 38:1183–1186 (1997).
U. Jonsson et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 11:620–627 (1991).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Astriab-Fisher, A., Sergueev, D., Fisher, M. et al. Conjugates of Antisense Oligonucleotides with the Tat and Antennapedia Cell-Penetrating Peptides: Effects on Cellular Uptake, Binding to Target Sequences, and Biologic Actions. Pharm Res 19, 744–754 (2002). https://doi.org/10.1023/A:1016136328329
Issue Date:
DOI: https://doi.org/10.1023/A:1016136328329